Despite the lack of genetic evidence for the potential differential contribution between CK2α’ and CK2α to AD pathology, several studies have proposed the role of CK2 in the phosphorylation of Tau (pTau) and tau-mediated pathology. The gene discussed is MAPT; the disease is Alzheimer disease.